Cytoplasmic steroid effects on nuclear RNA polymerase activity in canine mammary carcinomas.
DNA-dependent RNA polymerase activity has been studied in isolated nuclei from canine mammary tumours. Initial experiments showed high levels of RNase activity in this tissue; accordingly, routine assays were terminated before loss of acid-precipitable radioactivity was evident. RNA polymerase A and B activity in isolated nuclei were shown to be increased by addition of receptor-containing cytosol previously incubated with oestradiol-17 beta, dihydrotestosterone or R5020. Where no receptor was present, as measured by saturation binding assays and sucrose density gradient analysis, there was no corresponding increase in polymerase activity. The steroid antagonists tamoxifen and cyproterone did not elicit any response even when their corresponding steroids produced a 1- to 2-fold stimulation of polymerase activity. Steroid-induced effects proved to be dose-dependent, with half maximal responses for oestradiol-17 beta 8 X 10(-8)M, R5020 2 X 10(-6)M and dihydrotestosterone 9 X 10(-6)M.
D000818:Animals; D001665:Binding Sites; D002467:Cell Nucleus / Q000201:enzymology; D003534:Cyproterone / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism*; D004047:Diethyl Pyrocarbonate / Q000494:pharmacology; D013196:Dihydrotestosterone / Q000494:pharmacology; D004283:Dog Diseases / Q000201:enzymology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D008321:Mammary Glands, Animal; D009369:Neoplasms / Q000201:enzymology / Q000662:veterinary*; D011397:Promegestone / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology
D013196:Dihydrotestosterone; D013629:Tamoxifen; D004958:Estradiol; D011397:Promegestone; D003534:Cyproterone; D012321:DNA-Directed RNA Polymerases; D004047:Diethyl Pyrocarbonate